Printer Friendly

Reportlinker Adds Global Pediatric Drugs and Vaccines Industry.

NEW YORK, June 15, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Pediatric Drugs and Vaccines Industry

http://www.reportlinker.com/p0552789/Global-Pediatric-Drugs-and-Vaccines-Industry.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_

This report analyzes the worldwide markets for Pediatric Drugs and Vaccines in US$ Million by the following Product Segments: Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs, and Other Pediatric Drugs. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 159 companies including many key and niche players such as Abbott Laboratories, Allergan, Inc., Amgen, Inc., AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline Plc, Merck & Co., Inc., Merck Serono, Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Sanofi-Aventis, Shionogi, Inc., Shire Pharmaceuticals Group Plc, and UCB Pharma. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1

Study Reliability And Reporting Limitations 1

Disclaimers 2

Data Interpretation & Reporting Level 3

Quantitative Techniques & Analytics 3

Product Definitions and Scope Of Study 3

2. INDUSTRY OVERVIEW 4

Market Primer 4

Current & Future Analysis 4

Analysis by Region 4

Analysis by Segment 5

Pediatric Market - An Abode of Opportunities 5

Market to Witness Substantial Growth 5

3. MARKET TRENDS & ISSUES 6

Pediatric Exclusivity Drives Manufacturers' Interest 6

Large Unmet Needs Drive Growth in Various Segments 6

Prescription Hormone Drugs to Drive Market Growth 7

Issues Downplay Pharma Companies' Participation in Pediatric

Arena 7

High Off-Label Use Poses Challenges for Physicians 7

Use of CNS Therapeutics in Children Draws Huge Debate 7

Pediatric Vaccines Surge, Adult Vaccines Gain Traction 7

Table 1: Leading Players in the Global Vaccines Market

(2010): Market Share Breakdown of Revenues from Vaccines for

Merck, Sanofi-Pasteur, GlaxoSmithKline, Wyeth, and Others

(includes corresponding Graph/Chart) 8

Efforts to Ease Drug Use in Children Continues 8

Pediatric Drugs R&D Confronts Several Barriers 9

Barriers to the Development of Pediatric Drugs 9

Lack of Adequate Clinical Data - A Major Setback for the

Pediatric Market 9

Clinical Trials for Pediatric Drugs Face Several Roadblocks 9

Situation Alters As Several Drugs Enter Clinical Studies 10

Clinical Experience Remains Crucial for Cardiac Failure

Treatment Choice 10

Small Studies Offer Poor Basis for Decision Making 10

4. PEDIATRIC DISEASES - OVERVIEW, STATISTICS & TREATMENT 12

Infective Diseases 12

Allergy and Respiratory Diseases 12

Prevalence by Country 12

The US 12

Other Countries 12

Diphtheria 13

Incidence and Mortality Statistics 13

Upper Respiratory Infection (Common Cold) 13

Diagnosis & Treatment 13

Measles 14

Statistics 14

Asthma 14

Prevalence 15

Influenza 15

Treatment 15

Urinary Tract Infection (UTI) 16

Prevalence 16

Treatment 16

Mumps 16

Complications Related to Mumps 17

Prevention of Mumps in children 17

Incidence 17

Candidiasis 17

Fifth disease 18

Molluscum contagiosum 18

Roseola 18

Tetanus 19

Whooping Cough 19

Cancers 20

Brain Tumors 20

Prevalence 20

Leukemia 20

Prevalence 21

Lymphomas 21

Prevalence 21

Retinoblastoma 22

Prevalence 22

Ewing's Sarcoma 22

Symptoms and Treatment 23

Prevalence 23

Wilms' Tumor 24

Stages and Treatment 24

Prevalence & Incidence 24

Children's Rhabdomyosarcoma 24

Symptoms and Signs 25

Treatment 25

Statistics 26

Neuroblastoma 26

Symptoms 26

Treatment 27

Osteogenic Sarcoma 27

Prevalence 27

Symptoms and Treatment 27

Central Nervous System Disorders 28

Mental Disorders 28

Prevalence 28

Attention Deficit Hyperactivity Disorder 29

Prevalence 29

Depression 29

Prevalence 29

Epilepsy 30

Epilepsy Treatment 30

Incidence and Prevalence of Epilepsy in the US 30

Cardiovascular Diseases 31

Hypertension 31

Causes of Hypertension in Children 31

Symptoms of High Blood Pressure 32

Treatment 32

Autoimmune Diseases 32

Juvenile Rheumatoid Arthritis 32

Prevalence 33

Hormonal Disorders 33

Diabetes Mellitus 33

Hypothyroidism 33

Hypothyroidism in Infants and Children 34

Symptoms and Diagnosis 34

Treatment of Hypothyroidism in Children 34

Precocious Puberty 35

Symptoms and Signs 35

Treatment 35

Hypopituitarism 36

Treatment 36

Lymphocytic Thyroiditis 36

Symptoms 37

Treatment 37

Other Diseases 37

Pain 37

Pain Control Medicines for Children 37

Statistics 37

Cystic Fibrosis 38

Meningitis 38

Down Syndrome 39

Nephrotic Syndrome 39

Rickets 40

Sever's Disease 40

Xerophthalmia 40

Enuresis 41

Treatment 41

Dental Caries 41

Malaria 42

Leprosy 42

Poliomyelitis 42

Diarrhea 43

Inflammatory Bowel Disease (IBD) 43

Symptoms 43

Treatment 43

Anemia 43

Treatment for Anemia in Children 44

Irritable Bowel Syndrome (IBS) 44

Causes & Symptoms 45

Treatment 45

5. REGULATORY SCENARIO 46

Laws for Pediatric Drugs 46

Legislations for Pediatric Drug Trials 46

International Conference on Harmonisation (ICH) Guidelines for

Pediatric Formulations 47

6. PRODUCT APPROVALS AND LAUNCHES 48

Select Pediatric and Adolescent Drug Approvals (2008-2010) 48

Shire Receives Health Canada Approval for VPRIV for Treating

Gaucher Disease 49

Shionogi Obtains Extended Approval for Kapvay from FDA 49

Stiefel Obtains US FDA Approval for Veltin 50

Merck Obtains US FDA Approval for Dulera 50

Shire Obtains FDA Approval for VPRIV for Treating Type 1

Gaucher Disease 50

Prestige Brands Launches Pediatric OTC Product, Little Fevers 51

Shionogi Obtains FDA Approval for Cuvposa 51

Orphan Europe Receives FDA Approval for Carbaglu 52

Eisai Obtains Approval for Tambocor in Japan 52

AccuDial Launches New Pediatric Medications in Canada 52

Matrix Obtains Tentative FDA Approval for Efavirenz Tablets

Under PEPFAR 52

Lilly Obtains FDA Clearance for Two Adolescent Indications of

Zyprexa 53

AstraZeneca Obtains FDA Approval for CRESTOR in Treating HeFH

In Children 53

CSL Behring Receives FDA Approval for Berinert In HAE Treatment 53

Baxter Unveils HYLENEX Recombinant for Pediatric Rehydration 54

Shire Obtains FDA Clearance for Intuniv for Treating ADHD 54

Roche Obtains FDA Approval for Valcyte to Prevent

Cytomegalovirus Disease in Pediatrics 55

Lundbeck Obtains FDA Approval for Sabril 55

GSK Receives FDA Approval for Hiberix Vaccine for Use in

Preventing Hib 56

Novartis Obtains Approval for Ilaris in the US to Treat CAPS 56

Novartis Launches Cherry-Flavored Coartem Dispersible Tablets

in African Countries 57

Elan Pharmaceuticals Obtains US FDA Approval for Banzel 57

Lev Obtains FDA Approval for Cinryze to Treat Angioedema

Attacks in Adolescents and Adults 58

GSK Receives FDA Approval for Rotarix Vaccine for Treating

Rotavirus Gastroenteritis 58

Alcon Receives FDA Approval for Patanase For Treating Seasonal

Allergic Rhinitis 59

Boehringer Ingelheim Receives FDA Approval for Aptivus Oral

Solution 60

Bristol-Myers Squibb Obtains US FDA Approval for Orencia 61

Abbott Obtains Marketing Approval for Pediatric Kaletra

Tablets in Europe 61

AstraZeneca's Nexium Receives FDA Approval for Treating

Pediatric GERD 62

BMS Obtains FDA Approval for Abilify for Treating Pediatric

Bipolar Disorder 62

MiddleBrooke Obtains FDA Approval for Moxatag to Treat

Tonsillitis in Children and Adult Patients 62

Cangene Obtains FDA Approval for Accretropin to Treat Growth

Failure In Pediatric Patients 63

Sanofi-aventis and UCB Launch Prescription Allergy Drug,

Xyzal in the US 63

FDA Clears Veramyst(TM) Nasal Spray for Treating Allergy 64

7. DRUG PIPELINE ANALYSIS 65

Table 2: Pediatric Drugs Pipeline By Select Disease Areas

(2010): Number of Drugs Under Development for Genetic

Diseases, Infectious Diseases, Cancer, Neurological Diseases,

Vaccines, Respiratory Diseases, Psychiatric Diseases,

Cardiovascular Ailments, GI Diseases, Eye Diseases and Others

(includes corresponding Graph/Chart) 65

Select Pediatric Drugs Filed for Approval 65

Select Pediatric Drugs in Phase III Clinical Development 66

Select Pediatric Drugs in Phase II Clinical Development 70

Select Pediatric Drugs in Phase I Clinical Development 74

8. RECENT INDUSTRY ACTIVITY 76

HealthSport Collaborates with CURE Pharma to Develop

Healthcare Products 76

Pfizer Japan to Develop Pediatric Versions of Three Drugs 76

Honey Naturals Signs Agreement with Invicta Group to Represent

ZarBee's 76

Eisai to File for Approval of Pediatric Heartburn Drug in the US 76

Sunflower Pharma Obtains Patent for Pediatric Drug 76

Shionogi Intends to File for Peramivir Approval in Japan for

Pediatrics 77

Shanghai Children's Medical Center Establishes Pediatric

Institute 77

Pfizer Takes Over Wyeth 77

Lid Hair Studios Enters into a Reverse Merger Agreement with

Shaanxi Jiali 77

AstraZeneca Discontinues License Agreement with MAP

Pharmaceuticals 78

Argentech to Purchase Marketing Rights to Opti-Silver 78

FDA Mulls Over Clearing Psychiatric Drugs for Adolescents 78

Hubei Beike Collaborates with Stada Arzneimittel 78

Korosho to Expedite Pediatric and Anti-Cancer Drug Development 79

Hubei Beike and Hubei Wushi to Set Up Drug Manufacturing Facility 79

Sanofi-Pasteur to Commence Pediatric Trials for its Dengue

Vaccine 79

Novartis and Medicines Malaria Venture Receives Grant from

ExxonMobil 79

Sunstone (Tangshan) Pharmaceutical to Acquire Majority Stake

in Zhangjiakou Shengda Pharmaceutical 79

Lux Biosciences Receives Positive Opinion from EMEA for

Pediatric Investigation Plan for LUVENIQ 80

IFPMA Takes Steps to Advance Pediatric Drug Access 80

FDA Confers Orphan Drug Status to Cancer Treatment Drug 80

Ipsen Acquires Tercica 81

Shionogi Acquires Sciele Pharma 81

Sunstone Obtains Production License from SFDA of China for

Pediatric Multivitamins 81

Madeira Therapeutics Comes into Existence 81

Beijing Med-Pharm Acquires Sunstone Pharmaceutical Co. 82

Malvern's Myobloc Comes Under FDA Scanner 82

9. FOCUS ON SELECT GLOBAL PLAYERS 83

Abbott Laboratories (US) 83

Allergan, Inc. (US) 83

Amgen, Inc. (US) 83

AstraZeneca Plc. (UK) 83

Boehringer Ingelheim GmbH (Germany) 84

Bristol-Myers Squibb Company (US) 84

Eli Lilly and Company (US) 84

F. Hoffmann-La Roche Ltd. (Switzerland) 85

Genentech, Inc. (US) 85

GlaxoSmithKline Plc. (UK) 86

Merck & Co., Inc. (US) 86

Merck Serono (Switzerland) 86

Novartis AG (Switzerland) 87

Novo Nordisk A/S (Denmark) 88

Pfizer, Inc. (US) 88

Sanofi-Aventis (France) 89

Shionogi, Inc. (US) 89

Shire Pharmaceuticals Group Plc. (US) 90

UCB Pharma (Belgium) 90

10. GLOBAL MARKET PERSPECTIVE 91

Table 3: World Recent Past, Current & Future Analysis for

Pediatric Drugs and Vaccines by Geographic Region - US,

Europe, Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Revenue Figures in US$

Million for Years 2009 through 2017 (includes corresponding

Graph/Chart) 91

Table 4: World Historic Review for Pediatric Drugs and

Vaccines by Geographic Region - US, Europe, Asia-Pacific,

Latin America and Rest of World Markets Independently Analyzed

with Annual Revenue Figures in US$ Million for Years 2003

through 2008 (includes corresponding Graph/Chart) 92

Table 5: World 15-Year Perspective for Pediatric Drugs and

Vaccines by Geographic Region - Percentage Share Breakdown of

Dollar Sales for US, Europe, Asia-Pacific, Latin America and

Rest of World Markets for Years 2003, 2010 and 2017 (includes

corresponding Graph/Chart) 93

Analysis By Segment 94

Table 6: World Recent Past, Current & Future Analysis for

Pediatric Vaccines by Geographic Region - US, Europe,

Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Revenue Figures in US$

Million for Years 2009 through 2017 (includes corresponding

Graph/Chart) 94

Table 7: World Historic Review for Pediatric Vaccines by

Geographic Region - US, Europe, Asia-Pacific, Latin America

and Rest of World Markets Independently Analyzed with Annual

Revenue Figures in US$ Million for Years 2003 through 2008

(includes corresponding Graph/Chart) 95

Table 8: World 15-Year Perspective for Pediatric Vaccines by

Geographic Region - Percentage Share Breakdown of Dollar Sales

for US, Europe, Asia-Pacific, Latin America and Rest of World

Markets for Years 2003, 2010 and 2017 (includes corresponding

Graph/Chart) 96

Table 9: World Recent Past, Current & Future Analysis for

Pediatric Hormones by Geographic Region - US, Europe,

Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Revenue Figures in US$

Million for Years 2009 through 2017 (includes corresponding

Graph/Chart) 97

Table 10: World Historic Review for Pediatric Hormones by

Geographic Region - US, Europe, Asia-Pacific, Latin America

and Rest of World Markets Independently Analyzed with Annual

Revenue Figures in US$ Million for Years 2003 through 2008

(includes corresponding Graph/Chart) 98

Table 11: World 15-Year Perspective for Pediatric Hormones by

Geographic Region - Percentage Share Breakdown of Dollar Sales

for US, Europe, Asia-Pacific, Latin America and Rest of World

Markets for Years 2003, 2010 and 2017 (includes corresponding

Graph/Chart) 99

Table 12: World Recent Past, Current & Future Analysis for

Pediatric Allergy & Respiratory Drugs by Geographic Region -

US, Europe, Asia-Pacific, Latin America and Rest of World

Markets Independently Analyzed with Annual Revenue Figures in

US$ Million for Years 2009 through 2017 (includes

corresponding Graph/Chart) 100

Table 13: World Historic Review for Pediatric Allergy &

Respiratory Drugs by Geographic Region - US, Europe,

Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Revenue Figures in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) 101

Table 14: World 15-Year Perspective for Pediatric Allergy &

Respiratory Drugs by Geographic Region - Percentage Share

Breakdown of Dollar Sales for US, Europe, Asia-Pacific, Latin

America and Rest of World Markets for Years 2003, 2010 and

2017 (includes corresponding Graph/Chart) 102

Table 15: World Recent Past, Current & Future Analysis for

Pediatric Anti-infective Drugs by Geographic Region - US,

Europe, Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Revenue Figures in US$

Million for Years 2009 through 2017 (includes corresponding

Graph/Chart) 103

Table 16: World Historic Review for Pediatric Anti-infective

Drugs by Geographic Region - US, Europe, Asia-Pacific, Latin

America and Rest of World Markets Independently Analyzed with

Annual Revenue Figures in US$ Million for Years 2003 through

2008 (includes corresponding Graph/Chart) 104

Table 17: World 15-Year Perspective for Pediatric Anti-

infective Drugs by Geographic Region - Percentage Share

Breakdown of Dollar Sales for US, Europe, Asia-Pacific, Latin

America and Rest of World Markets for Years 2003, 2010 and

2017 (includes corresponding Graph/Chart) 105

Table 18: World Recent Past, Current & Future Analysis for

Pediatric CNS Drugs by Geographic Region - US, Europe,

Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Revenue Figures in US$

Million for Years 2009 through 2017 (includes corresponding

Graph/Chart) 106

Table 19: World Historic Review for Pediatric CNS Drugs by

Geographic Region - US, Europe, Asia-Pacific, Latin America

and Rest of World Markets Independently Analyzed with Annual

Revenue Figures in US$ Million for Years 2003 through 2008

(includes corresponding Graph/Chart) 107

Table 20: World 15-Year Perspective for Pediatric CNS Drugs by

Geographic Region - Percentage Share Breakdown of Dollar Sales

for US, Europe, Asia-Pacific, Latin America and Rest of World

Markets for Years 2003, 2010 and 2017 (includes corresponding

Graph/Chart) 108

Table 21: World Recent Past, Current & Future Analysis for

Other Pediatric Drugs by Geographic Region - US, Europe,

Asia-Pacific, Latin America and Rest of World Markets

Independently Analyzed with Annual Revenue Figures in US$

Million for Years 2009 through 2017 (includes corresponding

Graph/Chart) 109

Table 22: World Historic Review for Other Pediatric Drugs by

Geographic Region - US, Europe, Asia-Pacific, Latin America

and Rest of World Markets Independently Analyzed with Annual

Revenue Figures in US$ Million for Years 2003 through 2008

(includes corresponding Graph/Chart) 110

Table 23: World 15-Year Perspective for Other Pediatric Drugs

by Geographic Region - Percentage Share Breakdown of Dollar

Sales for US, Europe, Asia-Pacific, Latin America and Rest of

World Markets for Years 2003, 2010 and 2017 (includes

corresponding Graph/Chart) 111

11. THE UNITED STATES 112

A.Market Analysis 112

Current & Future Analysis 112

Pediatric Drugs Performance Over the Years 112

Market Expansion On the Cards, Market Restraints to Check

Growth 112

Major Diseases Afflicting Children 113

Spending on Pediatric Medicines Surges 113

Drug Use Rises Among Children in Various Disease Areas 114

CNS Drugs Too Witness Increases in Use 114

Pediatric Antidepressant Drugs and Black Box Warnings 115

List of Drugs Mandated by FDA to Carry Black Box Warning on

Suicidal Ideation in Adolescents and Children 115

Pediatric Cough & Cold OTC Segment Marred with Safety and

Dosing Issues 116

Safety Issues Alter Market Dynamics In OTC Analgesics 117

Ad Spending by Pediatric OTC Drugs Manufacturers 117

Table 24: Leading Players in Pediatric OTC Drugs Market by

Ad Spending (2008): Ad Spending in US$ Million for Johnson &

Johnson, Wyeth Consumer Healthcare, Schering-Plough

Corp., Pfizer Inc., Vetco Inc., Novartis AG, and Beiersdorf

Inc. (includes corresponding Graph/Chart) 117

US Pediatric Legislation 118

Product Launches/Approvals 118

Strategic Corporate Developments 129

Focus on Select Major Players 131

Abbott Laboratories 131

Allergan, Inc. 132

Amgen, Inc 132

Bristol-Myers Squibb Company 132

Eli Lilly and Company 132

Genentech, Inc. 133

Merck & Co. Inc. 133

Pfizer, Inc. 133

Shionogi, Inc. 134

Shire Pharmaceuticals Group PLC 134

B.Market Analytics 135

Table 25: US Recent Past, Current & Future Analysis for

Pediatric Drugs and Vaccines Market by Segment - Pediatric

Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs,

Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs

Market Independently Analyzed with Annual Revenues in US$

Million for Years 2009 through 2017 (includes corresponding

Graph/Chart) 135

Table 26: US Historic Review for Pediatric Drugs and

Vaccines Market by Segment - Pediatric Vaccines, Pediatric

Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs,

CNS Drugs and Other Pediatric Drugs Market Independently

Analyzed with Annual Revenues in US$ Million for Years 2003

through 2008 (includes corresponding Graph/Chart) 136

Table 27: US 15-Year Perspective for Pediatric Drugs and

Vaccines Market by Segment - Percentage Breakdown of Dollar

Revenues for Pediatric Vaccines, Pediatric Hormones, Allergy &

Respiratory Drugs, Anti-infective Drugs, CNS Drugs and

Other Pediatric Drugs Market for Years 2003, 2010 & 2017

(includes corresponding Graph/Chart) 137

12. EUROPE 138

A.Market Analysis 138

Current & Future Analysis 138

Overview of European Pediatric Drugs Industry 138

European Legislation for Pediatric Medications 138

Pediatric Regulation 138

Improvement in European Clinical Trials 139

Product Approval 139

Strategic Corporate Development 140

B.Market Analytics 140

Table 28: European Recent Past, Current & Future Analysis

for Pediatric Drugs and Vaccines by Geographic Region -

France, Germany, Italy, UK, Spain and Rest of Europe -

Markets Independently Analyzed with Annual Revenues in US$

Million for Years 2009 through 2017 (includes corresponding

Graph/Chart) 140

Table 29: European Historic Review for Pediatric Drugs and

Vaccines by Geographic Region -France, Germany, Italy, UK,

Spain and Rest of Europe - Markets Independently Analyzed

with Annual Revenues in US$ Million for Years 2003 through

2008 (includes corresponding Graph/Chart) 141

Table 30: European 15-Year Perspective for Pediatric Drugs

and Vaccines by Geographic Region - Percentage Breakdown of

Dollar Revenues for France, Germany, Italy, UK, Spain and

Rest of Europe Markets for Years 2003, 2010 & 2017 (includes

corresponding Graph/Chart) 142

Table 31: European Recent Past, Current & Future Analysis

for Pediatric Drugs and Vaccines Market by Segment -

Pediatric Vaccines, Pediatric Hormones, Allergy &

Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other

Pediatric Drugs Market Independently Analyzed with Annual

Revenues in US$ Million for Years 2009 through 2017

(includes corresponding Graph/Chart) 143

Table 32: European Historic Review for Pediatric Drugs and

Vaccines Market by Segment - Pediatric Vaccines, Pediatric

Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs,

CNS Drugs and Other Pediatric Drugs Market Independently

Analyzed with Annual Revenues in US$ Million for Years 2003

through 2008 (includes corresponding Graph/Chart) 144

Table 33: European 15-Year Perspective for Pediatric Drugs

and Vaccines Market by Segment - Percentage Breakdown of

Dollar Revenues for Pediatric Vaccines, Pediatric Hormones,

Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs

and Other Pediatric Drugs Market for Years 2003, 2010 & 2017

(includes corresponding Graph/Chart) 145

12a. FRANCE 146

A.Market Analysis 146

Current & Future Analysis 146

Strategic Corporate Development 146

Key Player 146

Sanofi-Aventis 146

B.Market Analytics 147

Table 34: French Recent Past, Current & Future Analysis for

Pediatric Drugs Market Analyzed with Annual Revenues in US$

Million for Years 2009 through 2017 (includes corresponding

Graph/Chart) 147

Table 35: French Historic Review for Pediatric Drugs and

Vaccines Market Analyzed with Annual Revenues in US$ Million

for Years 2003 through 2008 (includes corresponding

Graph/Chart) 148

12b. GERMANY 149

A.Market Analysis 149

Current and Future Analysis 149

Strategic Corporate Development 149

Key Player 149

Boehringer Ingelheim GmbH 149

B.Market Analytics 150

Table 36: German Recent Past, Current & Future Analysis for

Pediatric Drugs and Vaccines Market Analyzed with Annual

Revenues in US$ Million for Years 2009 through 2017

(includes corresponding Graph/Chart) 150

Table 37: German Historic Review for Pediatric Drugs and

Vaccines Market Analyzed with Annual Revenues in US$ Million

for Years 2003 through 2008 (includes corresponding

Graph/Chart) 150

12c. ITALY 151

Market Analysis 151

Table 38: Italian Recent Past, Current & Future Analysis for

Pediatric Drugs and Vaccines Market Analyzed with Annual

Revenues in US$ Million for Years 2009 through 2017

(includes corresponding Graph/Chart) 151

Table 39: Italian Historic Review for Pediatric Drugs and

Vaccines Market Analyzed with Annual Revenues in US$ Million

for Years 2003 through 2008 (includes corresponding

Graph/Chart) 152

12d. THE UNITED KINGDOM 153

A.Market Analysis 153

Current & Future Analysis 153

Strategic Corporate Development 153

Key Players 153

AstraZeneca PLC 153

GlaxoSmithKline Plc 154

B.Market Analytics 155

Table 40: The UK Recent Past, Current & Future Analysis for

Pediatric Drugs and Vaccines Market Analyzed with Annual

Revenues in US$ Million for Years 2009 through 2017

(includes corresponding Graph/Chart) 155

Table 41: The UK Historic Review for Pediatric Drugs and

Vaccines Market Analyzed with Annual Revenues in US$ Million

for Years 2003 through 2008 (includes corresponding

Graph/Chart) 155

12e. SPAIN 156

Market Analysis 156

Table 42: Spanish Recent Past, Current & Future Analysis for

Pediatric Drugs and Vaccines Market Analyzed with Annual

Revenues in US$ Million for Years 2009 through 2017

(includes corresponding Graph/Chart) 156

Table 43: Spanish Historic Review for Pediatric Drugs and

Vaccines Market Analyzed with Annual Revenues in US$ Million

for Years 2003 through 2008 (includes corresponding

Graph/Chart) 157

12f. REST OF EUROPE 158

A.Market Analysis 158

Current & Future Analysis 158

Strategic Corporate Development 158

Key Players 158

F. Hoffmann-La Roche Ltd. (Switzerland) 158

Novartis AG (Switzerland) 159

Novo Nordisk A/S (Denmark) 160

UCB Pharma (Belgium) 160

B.Market Analytics 160

Table 44: Rest of Europe Recent Past, Current & Future

Analysis for Pediatric Drugs and Vaccines Market Analyzed

with Annual Revenues in US$ Million for Years 2009 through

2017 (includes corresponding Graph/Chart) 160

Table 45: Rest of Europe Historic Review for Pediatric Drugs

and Vaccines Market Analyzed with Annual Revenues in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) 161

13. ASIA-PACIFIC 162

A.Market Analysis 162

Current & Future Analysis 162

Growing Pediatric Market in China 162

Strategic Corporate Developments 162

B.Market Analytics 164

Table 46: Asia-Pacific Recent Past, Current & Future

Analysis for Pediatric Drugs and Vaccines Market by Segment -

Pediatric Vaccines, Pediatric Hormones, Allergy &

Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other

Pediatric Drugs Market Independently Analyzed with Annual

Revenues in US$ Million for Years 2009 through 2017

(includes corresponding Graph/Chart) 164

Table 47: Asia-Pacific Historic Review for Pediatric Drugs

and Vaccines Market by Segment - Pediatric Vaccines,

Pediatric Hormones, Allergy & Respiratory Drugs,

Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs

Market Independently Analyzed with Annual Revenues in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) 165

Table 48: Asia-Pacific 15-Year Perspective for Pediatric

Drugs and Vaccines Market by Segment - Percentage Breakdown

of Dollar Revenues for Pediatric Vaccines, Pediatric

Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs,

CNS Drugs and Other Pediatric Drugs Market for Years 2003,

2010 & 2017 (includes corresponding Graph/Chart) 166

14. LATIN AMERICA 167

Market Analysis 167

Table 49: Latin American Recent Past, Current & Future

Analysis for Pediatric Drugs and Vaccines Market by Segment -

Pediatric Vaccines, Pediatric Hormones, Allergy &

Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other

Pediatric Drugs Market Independently Analyzed with Annual

Revenues in US$ Million for Years 2009 through 2017

(includes corresponding Graph/Chart) 167

Table 50: Latin American Historic Review for Pediatric Drugs

and Vaccines Market by Segment - Pediatric Vaccines,

Pediatric Hormones, Allergy & Respiratory Drugs,

Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs

Market Independently Analyzed with Annual Revenues in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) 168

Table 51: Latin American 15-Year Perspective for Pediatric

Drugs and Vaccines Market by Segment - Percentage Breakdown

of Dollar Revenues for Pediatric Vaccines, Pediatric

Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs,

CNS Drugs and Other Pediatric Drugs Market for Years 2003,

2010 & 2017 (includes corresponding Graph/Chart) 169

15. REST OF WORLD 170

A.Market Analysis 170

Current & Future Analysis 170

Product Launches/Approvals 170

Strategic Corporate Developments 171

B.Market Analytics 172

Table 52: Rest of World Recent Past, Current & Future

Analysis for Pediatric Drugs and Vaccines Market by Segment -

Pediatric Vaccines, Pediatric Hormones, Allergy &

Respiratory Drugs, Anti-infective Drugs, CNS Drugs and Other

Pediatric Drugs Market Independently Analyzed with Annual

Revenues in US$ Million for Years 2009 through 2017

(includes corresponding Graph/Chart) 172

Table 53: Rest of World Historic Review for Pediatric Drugs

and Vaccines Market by Segment - Pediatric Vaccines,

Pediatric Hormones, Allergy & Respiratory Drugs,

Anti-infective Drugs, CNS Drugs and Other Pediatric Drugs

Market Independently Analyzed with Annual Revenues in US$

Million for Years 2003 through 2008 (includes corresponding

Graph/Chart) 173

Table 54: Rest of World 15-Year Perspective for Pediatric

Drugs and Vaccines Market by Segment - Percentage Breakdown

of Dollar Revenues for Pediatric Vaccines, Pediatric

Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs,

CNS Drugs and Other Pediatric Drugs Market for Years 2003,

2010 & 2017 (includes corresponding Graph/Chart) 174

COMPETITIVE LANDSCAPE

Total Companies Profiled: 159 (including Divisions/Subsidiaries - 178)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 118

Canada 5

Japan 4

Europe 36

France 4

Germany 5

The United Kingdom 4

Rest of Europe 23

Asia-Pacific (Excluding Japan) 12

Latin America 1

Middle-East 2

------------------------------------------

To order this report:

Drug and Medication Industry: Global Pediatric Drugs and Vaccines Industry

Drug and Medication Business News

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg Reportlinker Email: nbo@reportlinker.com US: (805)652-2626 Intl: +1 805-652-2626

SOURCE Reportlinker
COPYRIGHT 2011 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:90ASI
Date:Jun 15, 2011
Words:5859
Previous Article:Reportlinker Adds Global Medical Equipment Rental and Leasing Industry.
Next Article:Reportlinker Adds European Markets for Cosmetic Surgery, Facial Aesthetics and Medical Laser Devices 2011.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters